Novo Nordisk: The Market Hasn't Given It Enough Respect

Novo Nordisk (NVO) faces intense competitive pressure from Eli Lilly (LLY) in the diabetes and weight loss segment, which accounts for over 90% of its EBIT, compounded by a recent Goldman Sachs downgrade of the GLP-1 market's total addressable market. Despite concerns over next-gen product efficacy and potential pricing negotiations, NVO's stock has held above its multi-year lows from April, with its current valuation multiples suggesting significant pessimism is already priced in. The article maintains a "Buy" rating, arguing that NVO's stable profit margins and potential in a still-growing long-term market make it attractive for investors, implying the stock has potentially bottomed.

Analysis

Novo Nordisk (NVO) is navigating a period of intense pressure, with its stock performance lagging the broader market after hitting a multi-year low in April 2025. The company's significant operational concentration, with over 90% of its adjusted EBIT derived from the diabetes and obesity segment, heightens the risk from competitive and market-specific headwinds. Eli Lilly (LLY) has emerged as a formidable competitor, gaining US market share by more effectively managing supply chain constraints. Further threats loom from LLY's potentially more effective oral drug, orforglipron, and concerns that NVO's own next-generation product, CagriSema, underwhelmed in a recent study by achieving a 22.7% weight loss, below the suggested 25% target. This competitive landscape is compounded by a revised market outlook, evidenced by Goldman Sachs downgrading the 2030 GLP-1 total addressable market (TAM) by over 25% to $95 billion. Despite these challenges, a counter-narrative exists in the company's valuation. The market appears to have priced in a steep growth deceleration, with NVO's forward EBITDA multiple of approximately 11x approaching its 2016 low of 10.5x. The stock's ability to hold above its April lows suggests a potential bottoming process, supported by expectations of stable profit margins which underscore its established scale and market leadership.

Key Decisions for Investors

• Given the stock's valuation near historical lows and stabilization above its April nadir, investors with a long-term horizon might consider the current share price a contrarian opportunity, as significant pessimism regarding competition and market size appears to be priced in.
• Closely monitor competitive developments from Eli Lilly, particularly the clinical trial results and launch progress of its oral drug orforglipron, as this poses the most direct threat to Novo Nordisk's market dominance and future earnings power.
• Investors should watch for key catalysts such as the commercial uptake of NVO's oral semaglutide and any new efficacy data from its pipeline, as positive surprises could shift the current negative sentiment, while also tracking any further revisions to GLP-1 market size forecasts from major financial institutions.